Parameter
| Biomarker | miR-208a/b / miR-499 | Full name | MicroRNA-208a / MicroRNA-208b / MicroRNA-499 | Molecular Type | Non-coding RNA (miRNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | 22 nt | Core Functional Dimensions | Early diagnosis and prognosis |
| Disease | Coronary heart disease (CHD) | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Serum/plasma (RT-PCR, microfluidic chip) | ||
| Pathobiological Mechanisms | Myocardial high specificity (miR-208-a expression in myocardial only); Mir-208a is rapidly released after AMI and regulates myocardial contractile function related genes | ||||
| Clinical Availability Status | Clinical validation (key direction of early diagnosis) : the detection rate of miR-208a was 100% within 4 hours of AMI onset, the specificity was 100% (negative in non-AMI patients), and Mir-208a was listed as a "potential early marker" in the Diagnosis and Treatment Pathway of Acute chest Pain. The AUC of miR-499 in diagnosis of AMI was 0.994, which was positively correlated with infarct size | ||||
| Notes and Dynamics | The half-life of miR-208a is short (2h), which requires rapid detection. Joint miR-499 can improve prognosis evaluation effectiveness, both negative hint 30 d risk of adverse events < 1% | ||||